Paradoxical Effect of Myosteatosis on the Immune Checkpoint Inhibitor Response in Metastatic Renal Cell Carcinoma
Myosteatosis negatively impacts OS and PFS in patients with mRCC treated with PD-1 inhibitor + TKI therapy but is protective for PFS in those treated with PD-1 inhibitor + CTLA-4 inhibitor therapy. Altered checkpoint expression and immune cell composition associated with myosteatosis may contribute to these differential responses.
Authors
- Hyeonju Ahn (ORCID: https://orcid.org/0000-0002-8922-972X)
- Mi Ji Lee (ORCID: https://orcid.org/0000-0003-1364-1969)
- Woong‐Yang Park (ORCID: https://orcid.org/0000-0003-4234-0380)
- Wan Song (ORCID: https://orcid.org/0000-0003-0971-1805)
- Jiwoong Yu (ORCID: https://orcid.org/0000-0003-2147-2915)
- Byong Chang Jeong (ORCID: https://orcid.org/0000-0002-5399-2184)
- Hyun Hwan Sung (ORCID: https://orcid.org/0000-0001-9845-3742)
- Se Hoon Park (ORCID: https://orcid.org/0000-0001-5084-9326)
- Hwang Gyun Jeon (ORCID: https://orcid.org/0000-0002-5613-8389)
- Seong Soo Jeon (ORCID: https://orcid.org/0000-0002-3265-6261)
- Seong Il Seo (ORCID: https://orcid.org/0000-0002-9792-7798)
- Kyung Yeon Han (ORCID: https://orcid.org/0000-0001-9914-7763)
- Minyong Kang (ORCID: https://orcid.org/0000-0002-6966-8813)
Institutions
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1002/jcsm.13758
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.32
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- Ministry of Science and ICT, South Korea
- Samsung